claim: sars-cov-2 differs from sars-cov in the requirements for receptor expression and proteolytic activation to trigger cell-cell fusion and is not inhibited by bromhexine
evidence_1: taken together, we observed robust sars-cov-2 spike protein-mediated cell-cell fusion that was not dependent on exogenous tmprss2 expression and that was not inhibited by bromhexine.", "we observed that cell-cell fusion by sars-cov-s and sars-cov2-s was not inhibited by bromhexine, and only sars-cov-s activity was slightly inhibited by ambroxol in the presence of tmprss2.", "according to our results the bromhexine-mediated enhancement was specific for sars-cov-2 spike protein and was not seen with vsv-g as fusion effector, nor did we observe significant effects with the sars-cov-2-s mutants and sars-cov-s (figs."
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  )